Pelaris, Lorrie-mae B.

HRN: 20-75-97  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/19/2022
CEFUROXIME 500MG (TAB)
07/19/2022
07/25/2022
ORAL
500mg
BID
RMLE
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueReproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: